Puma Biotechnology (PBYI) Share-based Compensation (2011 - 2026)

Puma Biotechnology (PBYI) has 15 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Share-based Compensation fell 16.09% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 78.46% YoY) and the FY2025 annual result came in at $6.9 million, down 15.78% from the prior year.
• Share-based Compensation grew to $1.7 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q2 2022 to a low of $700000.0 in Q3 2025.
• A 5-year average of $2.2 million and a median of $2.4 million in 2024 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 117.78% in 2022, down 82.35% in 2022.
• Tracing PBYI's Share-based Compensation over 5 years: stood at $2.6 million in 2022, then slipped by 7.46% to $2.4 million in 2023, then fell by 27.96% to $1.8 million in 2024, then decreased by 7.71% to $1.6 million in 2025, then increased by 5.13% to $1.7 million in 2026.
• The last three Share-based Compensation figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.